Bayer's Novel Anticoagulant Xarelto^ Now Also Approved In The EU

The Bayer Group has achieved a major success in its product development: The European Commission has granted marketing approval for Xarelto^ (rivaroxaban), a novel anticoagulant taken as one tablet, once-daily, for the prevention of venous blood clots in adult patients undergoing elective (planned) hip or knee replacement surgery. Bayer HealthCare will start launching the product in the EU member states very soon.